(Total Views: 342)
Posted On: 12/15/2020 11:47:45 AM
Post# of 36566
Page 12, bolding mine:
The $574,328 increase in general and administrative expenses for the three months ended October 31, 2020 versus the comparative period in the prior period is due to primarily professional fees, which accounted for approximately $541,477 of the increase which includes $500,000 for consulting services in connection with obtaining regulatory approval for our Ii-Key-SARS-CoV-2 Peptide Vaccine in Malaysia. The Company also incurred $16,000 of accounting fees in relation to regulatory reporting. The $641,879 increase in research and development expenses for the three months ending October 31, 2020 versus the comparative period is due to testing the Ii-Key-SARS-CoV-2 Peptide Vaccine and laboratory testing and analysis. These research and development projects accounted for $171,129, and $567,062 of the total research and development expense.
The $574,328 increase in general and administrative expenses for the three months ended October 31, 2020 versus the comparative period in the prior period is due to primarily professional fees, which accounted for approximately $541,477 of the increase which includes $500,000 for consulting services in connection with obtaining regulatory approval for our Ii-Key-SARS-CoV-2 Peptide Vaccine in Malaysia. The Company also incurred $16,000 of accounting fees in relation to regulatory reporting. The $641,879 increase in research and development expenses for the three months ending October 31, 2020 versus the comparative period is due to testing the Ii-Key-SARS-CoV-2 Peptide Vaccine and laboratory testing and analysis. These research and development projects accounted for $171,129, and $567,062 of the total research and development expense.
(4)
(0)
